Clinical Validity of the DANU Sports System for Gait and Balance Assessment in Parkinson's Disease
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Northumbria University
- Enrollment
- 60
- Locations
- 2
- Primary Endpoint
- Stride Length
Overview
Brief Summary
This observational study aims to explore the use of the DANU Smart Socks for gait and balance assessment in people with Parkinson's (PwP). The study will compare walking and balance outcomes produced by DANU from people with Parkinson's (PwP) and a group of healthy individuals of similar age. The project aims to investigate if the gait and balance data collected are linked to measures of Parkinson's symptoms such as disease progression and cognitive abilities. Gait and balance outcomes will be obtained through one observational laboratory visit.
Detailed Description
Methods:
Institutional ethics have been obtained (Project ID: 8543). Utilising an observational design, participants will be asked to attend one visit to Northumbria University, Newcastle Upon Tyne.
Visit 1: Participants will complete a series of clinical and cognitive measures including the Movement Disorders Society's-Unified Parkinson's Disease Rating Scale, Montreal Cognitive Assessment, Freezing of Gait Questionnaire and Falls Efficacy Scale to act as descriptive measures. Following this, the investigators will conduct a concurrent data collection throughout a battery of motor tasks. The DANU system will be used alongside APDM Mobility Lab throughout the full duration of data collection. Mobility assessments include a 2-Minute Walk Test, 3 walkway trials, a Timed Up and Go and a series of 2-Minute Balance tasks.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Parkinson's Group Inclusion Criteria:- Clinical diagnosis of Parkinson's by a movement disorder specialist according to UK brain bank criteria.
- •PD stages I-III (Hoehn and Yahr Rating Scale)
- •Able to attend Northumbria University, Newcastle Upon Tyne for study visits.
- •Able to walk and stand unassisted for a minimum of 2-minutes.
- •Aged 50 years old or over
- •Parkinson's Group
Exclusion Criteria
- •History of neurological disorders other than PD (e.g., Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)
- •Unable to walk or stand unaided.
- •Montreal Cognitive Assessment (MoCA) score \< 21
- •Significant issues unrelated to PD that may affect gait (e.g., musculoskeletal issues, back pain, recent surgery etc.)
- •Healthy Control Inclusion Criteria:
- •Ability to attend Northumbria University, Newcastle Upon Tyne for study visits.
- •Aged 50 years old or over.
- •Able to walk and stand unassisted for a minimum of 2-minutes.
- •Healthy Control Exclusion Criteria:
- •History of neurological disorders (e.g. Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)
Arms & Interventions
Healthy Control (HC)
Aged-matched (over 50 years old) healthy controls who meet the described eligibility criteria will be recruited to participate in this study. The aim is to recruit 60 participants.
Parkinson's Disease (PD)
Participants with a clinical diagnosis of Parkinson's Disease meeting the described eligibility criteria will be recruited to take part within this study. The aim is to recruit 60 people with Parkinson's.
Outcomes
Primary Outcomes
Stride Length
Time Frame: Outcomes will be obtained in one visit (Day 1).
(m, mean ± standard deviation)
Step Time
Time Frame: Outcomes will be obtained in one visit (Day 1).
(s, mean ± standard deviation)
Stride Time
Time Frame: Outcomes will be obtained in one visit (Day 1).
(s, mean ± standard deviation)
Cadence
Time Frame: Outcomes will be obtained in one visit (Day 1).
(steps per minute, mean ± standard deviation)
Ground Contact Time
Time Frame: Outcomes will be obtained in one visit (Day 1).
(s, mean ± standard deviation)
Swing Time
Time Frame: Outcomes will be obtained in one visit (Day 1).
(s, mean ± standard deviation)
Stride Velocity
Time Frame: Outcomes will be obtained in one visit (Day 1).
(m/s, mean ± standard deviation)
Gait Velocity
Time Frame: Outcomes will be obtained in one visit (Day 1).
(m/s, mean ± standard deviation)
Area of Ellipse
Time Frame: Outcomes will be obtained in one visit (Day 1).
(mm², mean ± standard deviation)
Length of Ellipse
Time Frame: Outcomes will be obtained in one visit (Day 1).
(mm, mean ± standard deviation)
Width of Ellipse
Time Frame: Outcomes will be obtained in one visit (Day 1).
(mm, mean ± standard deviation)
Total Displacement
Time Frame: Outcomes will be obtained in one visit (Day 1).
(mm, mean ± standard deviation)
Medio-Lateral Range
Time Frame: Outcomes will be obtained in one visit (Day 1).
(mm, mean ± standard deviation)
Anterior-Posterior Range
Time Frame: Outcomes will be obtained in one visit (Day 1).
(mm, mean ± standard deviation)
Secondary Outcomes
No secondary outcomes reported
Investigators
GabriellaGatti
Postgraduate Research Student
Northumbria University